January 17, 2013                            Science Shaping our WorldBarbara S. Fox, PhD, CEOAvaxia Biologics128 Spring St...
Avaxia Biologics    Gut-targeted antibody therapeutics    • AVX-470: Oral anti-TNF antibody       – Phase 1b clinical tria...
Avaxia Biologics    • Located in Lexington, MA    • 13 FTEs    • Financing history: $16.4M raised to-date       – $5.8M no...
Avaxia Team    Management Team                           Board of Directors    • Barbara Fox, PhD                        •...
Inflammatory Bowel Disease    Ulcerative Colitis, Crohn’s Disease    • Serious chronic disease with no cure      – 2.5 mil...
AVX-470 for IBD    Anti-TNF antibody from colostrum of immunized cows                 •   Stable to digestion in GI tract ...
AVX-470 for Inflammatory Bowel Disease    Oral anti-TNF antibody as first line therapy                                    ...
8    AVX-470 for GI Acute Radiation Syndrome    Oral anti-TNF antibody stockpiled for defense    • US government (BARDA/HH...
Avaxia Biologics    Gut-targeted antibody therapeutics    • AVX-470: Oral anti-TNF antibody       – Phase 1b clinical tria...
Upcoming SlideShare
Loading in …5
×

Avaxia Biologics

1,033 views
865 views

Published on

Avaxia is a clinical-stage biotechnology company that is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal (GI) tract including the mouth, throat, and intestines. Avaxia’s proprietary oral antibody platform makes direct delivery of antibodies to the GI tract possible by overcoming some of the traditional limitations of antibody therapeutics. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia is developing gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome, and oral mucositis.

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,033
On SlideShare
0
From Embeds
0
Number of Embeds
16
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Avaxia Biologics

  1. 1. January 17, 2013 Science Shaping our WorldBarbara S. Fox, PhD, CEOAvaxia Biologics128 Spring St., Suite 620Lexington, MA 02421781-861-0062 x303bfox@avaxiabiologics.com
  2. 2. Avaxia Biologics Gut-targeted antibody therapeutics • AVX-470: Oral anti-TNF antibody – Phase 1b clinical trial in patients with active ulcerative colitis • AVX oral antibody platform – Game changing technology expands $50B antibody market • Full pipeline of products – Inflammatory bowel disease – GI acute radiation syndrome – Diabetes – Celiac disease2
  3. 3. Avaxia Biologics • Located in Lexington, MA • 13 FTEs • Financing history: $16.4M raised to-date – $5.8M non-dilutive funding • NIH grants, BARDA contract, Mass Life Science Center • Additional $1.7M pending from Department of Defense – $4.1M Series A November 2011 • Cherrystone Angels, Beacon Angels, Boston Harbor Angels, Launchpad Venture Group, Mass Medical Angels, North Country Angels and individuals – $6.5M Series B December 2012 • All Series A angel groups + Golden Seeds, Beta Fund, Granite State Angels, Maine Angels3
  4. 4. Avaxia Team Management Team Board of Directors • Barbara Fox, PhD • Barbara Fox, PhD, Avaxia – CEO & Founder • Nada Jain, Golden Seeds • David Dlesk – COO • Henry Kay, Launchpad, BHA • Daniel Tracey, PhD • Chris Kiritsy, Arisaph – VP Research • Rob Manning, Cherrystone • Eileen Bostwick, PhD – VP Development and QC • David Poorvin, PhD, Avaxia • Michael Rivard Scientific & Clin Advisors – VP Corporate Development • Scott Harris, MD • Robert Kamen, PhD – Chief Medical Officer (consulting) • Stephen Sonis, DMD, DMSc • Bruce Sands, MD4
  5. 5. Inflammatory Bowel Disease Ulcerative Colitis, Crohn’s Disease • Serious chronic disease with no cure – 2.5 million people, 1 million in US – Abdominal pain, diarrhea, high rate of surgery • Limited therapeutic options – Steroids - High efficacy but poor safety – 5-ASAs – Modest efficacy – Injected anti-TNF monoclonal antibodies • High efficacy, but systemic immunosuppression • Expensive, difficult dosing5
  6. 6. AVX-470 for IBD Anti-TNF antibody from colostrum of immunized cows • Stable to digestion in GI tract • Safe for oral delivery (lactose-free) • Minimal systemic exposure • High potency • Low cost of goods • Strong patent position6
  7. 7. AVX-470 for Inflammatory Bowel Disease Oral anti-TNF antibody as first line therapy AVX-470 treats IBD in • TNF is validated target mouse model • Deliver to the site of 3.0 inflammation Endoscopy Score 2.5 – Maintain efficacy – Safer due to limited * systemic exposure 2.0 • Position as first-line 1.5 therapy Saline control Steroid AVX-470 Control bovine antibody7
  8. 8. 8 AVX-470 for GI Acute Radiation Syndrome Oral anti-TNF antibody stockpiled for defense • US government (BARDA/HHS) is developing countermeasures to protect civilian population in event of nuclear attack • Avaxia awarded $3M BARDA contract July 2011 to develop AVX-470 for GI ARS 100 80 % Survival 60 Mice irradiated with 8Gy total body irradiation Dosed with saline or AVX-470, oral, once per day 40 Survival at day 10 post-irradiation 20 0 Saline AVX-470m8
  9. 9. Avaxia Biologics Gut-targeted antibody therapeutics • AVX-470: Oral anti-TNF antibody – Phase 1b clinical trial in patients with active ulcerative colitis • AVX oral antibody platform – Game changing technology expands $50B antibody market • Full pipeline of products – Inflammatory bowel disease – GI acute radiation syndrome – Diabetes – Celiac disease9

×